Health Care Weekly: SCOTUS Sides with Generic Drugmaker in Skinny Labeling Case; FDA, Congress Aim to Speed Up Investigational New Drug Applications; OpenEvidence Says Doximity Misled Pharmaceutical Advertisers; CMS to Launch GLP-1 Bridge Program in July; FDA 483s
SCOTUS rules in favor of generic drugmaker in “skinny labeling” case. On June 4, the Supreme Court issued a unanimous opinion to reverse a previous Federal Circuit ruling in a patent case filed by drugmaker Amarin (AMRN) against its generic competitor Hikma, ruling that Hikma had not...




